ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN
September 5, 2017
ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN
This is an automatically generated default intro template – please do not edit.
|
General information |
|
| Title: | ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN |
| Meta keywords: | |
| Meta description: | |
|
Images information |
|
| Images path absolute: | /home/jmedarr/public_html/images/stories/com_form2content/p2/f417 |
| Images path relative: | com_form2content/p2/f417 |
| Thumbs path absolute: | |
| Thumbs path relative: | |
|
Fields information |
|
| Article_Title: | ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN |
| Authors: | 1ADINA POP-MOLDOVAN, 1MIHAI-NELU TROFENCIUC, 1MARIA PUŞCHIŢĂ |
| Affiliation: | Faculty of Medicine, Pharmacy and Dental Medicine, “Vasile Goldiş” Western University of Arad Romania |
| Abstract: | Echocardiography is considered to be a top noninvasive method for monitoring current patients on chemotherapy. The purpose of this study was to determine optimal timing of cardiac function monitoring and the risk factors for early induced doxorubicin cardiotoxicity by echocardiographic monitoring a 50 consecutive patients group with oncological pathology undergoing Doxorubicin chemotherapy. Because early detection of cardiac involvement would be useful in order to prevent progression to intractable heart failure, into our study group these determinations leaded to anthracycline treatment interruption and start of heart failure treatment. Also, we recommend a strict monitoring including a 3 months follow-up after the initiation of therapy with doxorubicin, not just at 6 weeks or at 6 months; we find this protocol necessary to early prevent cardiotoxicity elements and to intervene where necessary. |
| Keywords: | anthracycline, echocardiography, doxorubicin, cardiotoxicity, cardiomyopathy |
| References: | Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–5. Lipshultz SE, Alvarez JA, Scully RE .Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525–33 Monsuez JJ, Charniot JC, Vignat N, et al. .Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144:3–15. Erdogan D, Yucel H, Alanoglu EG, et al.Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Turk Kardiyol Dern Ars 2016;39:646–53. Belham M, Kruger A, Mepham S, et al.Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007;9:409–14. Barry E, Alvarez JA, Scully RE, et al.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039–58. Gharib MI, Burnett AK. Chemotherapyinduced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2016;4:235–42. Galderisi M, Marra F, Esposito R, et al.Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007;5:4. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 2015;30:474–80. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788–94. Mornoş C, Petrescu L. Early detection of anthracycline- mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J PhysiolPharmacol. 2013;91(8):601-7. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158(2):294-301 Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2012;86:1697–700. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007;7:61–6. |
| Read_full_article: | pdf/vol19/iss3/1 JMA 2016 – POP MOLDOVAN – articol.pdf |
| Correspondence: | Pop-Moldovan Adina Faculty of Medicine, Pharmacy and Dental Medicine “VasileGoldiş” Western University of Arad, Romania Arad, 86 Liviu Rebreanu St. E-mail: ppmldvn68@yahoo.com |
 |
Read full article |
| Article Title: | ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN |
| Authors: | 1ADINA POP-MOLDOVAN, 1MIHAI-NELU TROFENCIUC, 1MARIA PUŞCHIŢĂ |
| Affiliation: | Faculty of Medicine, Pharmacy and Dental Medicine, “Vasile Goldiş” Western University of Arad Romania |
| Abstract: | Echocardiography is considered to be a top noninvasive method for monitoring current patients on chemotherapy. The purpose of this study was to determine optimal timing of cardiac function monitoring and the risk factors for early induced doxorubicin cardiotoxicity by echocardiographic monitoring a 50 consecutive patients group with oncological pathology undergoing Doxorubicin chemotherapy. Because early detection of cardiac involvement would be useful in order to prevent progression to intractable heart failure, into our study group these determinations leaded to anthracycline treatment interruption and start of heart failure treatment. Also, we recommend a strict monitoring including a 3 months follow-up after the initiation of therapy with doxorubicin, not just at 6 weeks or at 6 months; we find this protocol necessary to early prevent cardiotoxicity elements and to intervene where necessary. |
| Keywords: | anthracycline, echocardiography, doxorubicin, cardiotoxicity, cardiomyopathy |
| References: | Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–5. Lipshultz SE, Alvarez JA, Scully RE .Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525–33 Monsuez JJ, Charniot JC, Vignat N, et al. .Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144:3–15. Erdogan D, Yucel H, Alanoglu EG, et al.Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Turk Kardiyol Dern Ars 2016;39:646–53. Belham M, Kruger A, Mepham S, et al.Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007;9:409–14. Barry E, Alvarez JA, Scully RE, et al.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039–58. Gharib MI, Burnett AK. Chemotherapyinduced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2016;4:235–42. Galderisi M, Marra F, Esposito R, et al.Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007;5:4. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 2015;30:474–80. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788–94. Mornoş C, Petrescu L. Early detection of anthracycline- mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J PhysiolPharmacol. 2013;91(8):601-7. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009;158(2):294-301 Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2012;86:1697–700. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007;7:61–6. |
| *Correspondence: | Pop-Moldovan Adina Faculty of Medicine, Pharmacy and Dental Medicine “VasileGoldiş” Western University of Arad, Romania Arad, 86 Liviu Rebreanu St. E-mail: ppmldvn68@yahoo.com |
PREVALENCE OF ERECTILE DYSFUNCTION POST-STROKE, AND ASSOCIATED RISK FACTORS AND CO-MORBIDITIES
QUALITY OF LIFE ANALYSIS OF PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER WHO UNDERWENT UROLOGICAL PALLIATIVE TREATMENT
THE IMPLICATIONS OF LYMPHANGIOGENESIS IN LUNG SQUAMOUS CELL CARCINOMAS
About The Author
